In a first study, it is demonstrated that lung cancer cells bearing an activating mutation of epithermal growth factor receptor (EGFR) were sensitized to apoptosis by concurrent treatment of inhibitors targeting the NF-kappaB signaling pathway [49]. The gene discussed is EGFR; the disease is lung carcinoma.